The adaptive immune response is initiated through presentation of antigen to T cells by DCs. In the mouse, DCs can be broadly grouped into plasmacytoid DCs (pDCs) and conventional DCs (cDCs; earlier termed myeloid DCs). Mouse cDCs can be further subdivided into several DC types, which are apparently specialized for optimal antigen uptake, processing, and presentation to T cells in different body compartments (Steinman and Banchereau, 2007; Heath and Carbone, 2009; Segura and Villadangos, 2009). One particular type of antigen presentation is cross-presentation: in this case, extracellular antigen is not classically presented in the context of MHC-II but is instead shunted into the MHC-I presentation pathway (Bevan, 2006; Shen and Rock, 2006; Villadangos et al., 2007). CD8+ T cells can thus be activated by antigens taken up from the extracellular space and then differentiate into cytotoxic T cells. This mechanism is thought to be of major importance for the recognition of viral or bacterial antigens when DCs are not directly infected. In these instances, debris of cells that were infected and have subsequently undergone apoptosis as part of a cellular stress reaction is taken up and cross-presented by specialized DCs. Through this type of processing, the antigenic composition of the pathogen can become visible to the
CD8\(^+\) T cell immune system. In the mouse, extensive experimentation has demonstrated that within cDCs, CD8\(^+\) DCs are the most effective in antigen cross-presentation (den Haan et al., 2000; Iyoda et al., 2002; Schulz and Reis e Sousa, 2002; Heath et al., 2004). Whether mouse pDCs play a significant role in antigen presentation and more so in antigen cross-presentation is controversial (Colonna et al., 2004; Liu, 2005; Villadangos and Young, 2008).

We have recently shown in the mouse system that splenic CD8\(^+\) DCs (and their counterparts in other organs) are the only cells in the body expressing XCR1, a chemokine receptor with a unique ligand, XCL1 (Dorner et al., 2009). In vitro, XCL1 induces potent chemotaxis of XCR1\(^+\) CD8\(^+\) T cells. In vivo, XCL1 secreted by activated CD8\(^+\) T cells augments their expansion and differentiation into cytotoxic T cells when the antigen is cross-presented by CD8\(^+\) DCs in the context of MHC-I (Dorner et al., 2009). Collectively, these observations indicate that the XCL1–XCR1 communication axis optimizes the cooperation of antigen-specific CD8\(^+\) T cells with XCR1\(^+\) DCs, which cross-present antigen to them.

Based on our studies in the mouse, we were interested to determine whether human DCs express XCR1. Human DCs have been extensively phenotyped in the past and subdivided again into pDC and into CD1c\(^+\) (BDCA-1\(^+\)), CD16\(^+\), and CD141\(^+\) (BDCA-3\(^+\)) cDC subsets (Dzionek et al., 2000; MacDonald et al., 2002; Piccioli et al., 2007; for review see Ju et al., 2010). Meticulos gene expression analyses of all human and mouse DCs have recently revealed a large gene expression program shared by human and mouse pDCs, and also led to the suggestion that human CD141\(^+\) DCs correspond to mouse CD8\(^+\) DCs (Robbins et al., 2008). In spite of this groundbreaking work on the subdivision of human DCs into subsets, information on the function of human primary DCs remained very scarce, apparently because of the limitations imposed by the very low frequencies of DCs in human blood (CD1c\(^+\) DCs, 0.31 \pm 0.14\% SD; CD16\(^+\) DCs, 0.75 \pm 0.41\%; CD141\(^+\) DCs, 0.04 \pm 0.03\%; pDCs, 0.29 \pm 0.08\%; \(n = 8\); not depicted). Instead, antigen cross-presentation in the human system was essentially analyzed with DCs derived from monocytes in culture (Fonteneau et al., 2003), a system that may not reflect all of the functional properties of primary DCs.

In the present study, we demonstrate that CD141\(^+\) DCs are the only population in human blood that expresses the chemokine receptor XCR1. Human CD141\(^+\) DCs react to the chemokine XCL1 by mobilization of intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) and by strong chemotaxis in vitro. More importantly, our experiments demonstrate that primary CD141\(^+\) DCs excel in cross-presentation of antigen when directly compared with CD1c\(^+\) DCs, CD16\(^+\) DCs, and pDCs from the same donors. Collectively, these functional data strongly indicate that human CD141\(^+\) DCs are the homologue of mouse CD8\(^+\) DCs. At the same time, the professional capacity of human CD141\(^+\) DCs to cross-present antigen is of major interest in the ongoing quest to develop vaccines capable of inducing antiviral or antitumor cytotoxicity in the human.

### RESULTS

#### Strategy for identification and sorting of human cDC subsets

The highly restricted expression of XCR1 in subsets of mouse DCs was suggestive of a similarly restricted expression in the human. Therefore, we first established a reliable process for the identification and sorting of DC subsets from human blood. Although the phenotype of pDCs in human blood could be established unequivocally (Robinson et al., 1999; Dzionek et al., 2000), several differing approaches were undertaken to define human cDCs in the past (Dzionek et al., 2000; MacDonald et al., 2002; Lindstedt et al., 2005; Piccioli et al., 2007). Our strategy was based on the observation that all human blood cDCs express HLA-DR and CD11c (MacDonald et al., 2002), and on the conclusion that CD1c\(^+\) CD34\(^+\) cells should not be regarded as DCs (Piccioli et al., 2007). Using the gating depicted in Fig. 1, we were able to clearly define distinct populations within cDCs, which in total represent \(\sim 1.1\% \pm (0.38\%\) SD\) of PBMCs in human blood (not depicted). The cDCs are composed of subsets expressing CD16 (68.2 \pm 37.3\%), CD1c (28.2 \pm 12.7\%), and the very small subset expressing CD141 (3.6 \pm 2.7\%). This gating strategy was the basis for the isolation of all cDC subsets to a very high purity.

#### The chemokine receptor XCR1 is selectively expressed in human CD141\(^+\) DCs

To identify cells expressing XCR1 in the human, we set up a highly sensitive and specific quantitative RT–PCR (qRT-PCR), with forward and reverse primers in exons 1 and 3, respectively, and a probe in the noncoding region of exon 3 (F1, R1, and P1; Fig. 2). This assay gave a very low signal with PBMCs (\(\sim 300\) copies in 100 ng of total RNA; unpublished data). To identify the source of this signal, we isolated

---

**Figure 1. Strategy for defining human cDC subsets in the blood.** PBMCs from human blood were enriched by density gradient centrifugation and stained for the indicated cell-surface markers (for the mAb used for staining see Materials and methods). Flow sorting (after magnetic cell enrichment) was performed on the principle of the gating strategy shown. This approach allowed us to isolate CD304\(^+\) pDCs, CD16\(^+\) DCs, CD1c\(^+\) DCs, and CD141\(^+\) DCs to very high purities. The inset numbers represent the percentage of the gated cells in the respective gating step. FSC, forward scatter; SSC, side scatter.
phosphoinositide hydrolysis–dependent and inositol-1,4,5-trisphosphate–triggered mobilization of \( \text{Ca}^{2+} \) from storage organelles. Approximately 20% of the cells responded only to the positive control (a mixture of CCL2, CCL21, CXCL9, and CX3CL1, selected based on the data of Robbins et al. [2008]), and 10% gave no response (Fig. 3). CD1c+ and CD16+ DCs, although alive and reactive, failed to respond to XCL1 under identical conditions (unpublished data). These results indicate that XCR1 is expressed on the cell surface in the majority of CD141+ DCs and can transduce an activation signal upon binding of its chemokine ligand, XCL1.

**XCL1 selectively chemoattracts CD141+ DCs**

To test human XCL1 for chemotaxis, highly purified, flow-sorted DC subtypes were mixed at a ratio of ~20% CD141+, 40% CD16+, and 40% CD1c+ DCs (Fig. 4 A, Input DC) and assayed in a Transwell system. Without addition of a chemokine, only CD16+ DCs within this mixed population exhibited some background migration (Fig. 4 A). Upon addition of increasing amounts of XCL1, a selective migration of CD141+ DCs was observed (Fig. 4 A). At the optimal concentrations of XCL1 (100–1,000 ng/ml), >40% of all input CD141+ DCs migrated (in one experiment >70%). Checkerboard tests with XCL1 indicated true chemotaxis and not only chemokinesis (unpublished data). CD1c+ and CD16+ DCs responded to various concentrations of XCL1 only by background migration; positive controls with a mixture of the chemokines CCL2, CCL21, and CX3CL1 (Fig. 4 A, Migrated DC) ensured that this unresponsiveness to XCL1 was not caused by a general unresponsiveness of these DC subsets. In the literature, migration of T cells, B cells, NK cells, and granulocytes was repeatedly reported in response to various cell types from PBMCs to a very high purity (see Materials and methods) and subjected them to qRT-PCR. No signal was obtained in T cells, B cells, NK cells, granulocytes, monocytes, pDCs, CD1c+ DCs, and CD16+ DCs (Fig. 2 B). In contrast, a strong XCR1 signal (~700,000 copies in 100 ng of total RNA) was obtained with CD141+ DCs (Fig. 2 B). In addition, we tested monocyte-derived DCs (MoDCs) in culture and found them to be negative (Fig. 2 B).

To exclude cell-specific expression of a XCR1 splice variant, we used a primer set within the coding region of XCR1 for the qRT-PCR (F2, R2, and P2; Fig. 2 A) and obtained identical results (not depicted). In all assays, the \( \beta2 \)-microglobulin signal was used as a positive control (unpublished data). Collectively, these experiments determined that in human blood, XCR1 is only expressed in CD141+ DCs.

**XCL1 mobilizes \( \text{Ca}^{2+} \) in CD141+ DCs but not in CD1c+ and CD16+ DCs**

To test the function of XCR1 in human CD141+ DCs, we isolated this subset as well as the other cDC subsets from human blood (purity in all instances was >98.7%) and exposed them to XCL1. In a single-cell \( \text{Ca}^{2+} \) assay, ~70% of all fura-2–loaded CD141+ DCs responded to XCL1 with a characteristic transient increase in \([\text{Ca}^{2+}]_{i}\) indicative of a phosphoinositide hydrolysis–dependent and inositol-1,4,5-trisphosphate–triggered mobilization of \( \text{Ca}^{2+} \) from storage organelles. Approximately 20% of the cells responded only to the positive control (a mixture of CCL2, CCL21, CXCL9, and CX3CL1, selected based on the data of Robbins et al. [2008]), and 10% gave no response (Fig. 3). CD1c+ and CD16+ DCs, although alive and reactive, failed to respond to XCL1 under identical conditions (unpublished data). These results indicate that XCR1 is expressed on the cell surface in the majority of CD141+ DCs and can transduce an activation signal upon binding of its chemokine ligand, XCL1.

**Figure 2.** The chemokine receptor XCR1 is selectively expressed in CD141+ DCs. (A) Organization of the human XCR1 gene (E1, exon 1; E2, exon 2; and E3, exon 3); the coding region is shown in black, and the primer–probe sets used for expression analyses are indicated. (B) qRT-PCR of total RNA from T cells, B cells, NK cells, granulocytes, monocytes, pDCs, CD1c+ DCs, CD16+ DCs, and CD141+ DCs isolated to a very high purity (>97.5%) from PBMCs and tested with primer–probe set 1 (F1, R1, and probe P1). Cultured MoDCs were also tested. Identical results were obtained using primer–probe set 2 (F2, R2, and P2; not depicted). The test systems used allowed the detection of ≥200 copies of XCR1 in cDNA reverse transcribed from 100 ng of total RNA. All PCR analyses were performed with cell subsets from at least two donors. Error bars represent means ± SEM.

**Figure 3.** XCL1 induces a \([\text{Ca}^{2+}]_{i}\) signal in CD141+ DCs. CD141+ DCs were flow sorted to a purity >98.7%, immobilized on poly-L-lysine-coated glass coverslips, and loaded with 2 μM fura-2/AM. Cells were imaged in a monochromator-assisted digital video imaging system and challenged with 1 μg/ml XCL1 as indicated (left arrow). Subsequently, the same cells were challenged again with a mixture of 100 ng/ml CCL2, 200 ng/ml CCL21, 200 ng/ml CXCL9, and 1 ng/ml CX3CL1 used as a positive control (right arrow). The data shown represent \([\text{Ca}^{2+}]_{i}\), concentrations of 300 single cells (gray lines) measured in two independent experiments. The mean \([\text{Ca}^{2+}]_{i}\), signal averaged over all cells responding to XCL1 is indicated (black line).
XCL1 (for a compilation of references see Dorner et al., 2009). When we performed analogous Transwell experiments, XCL1 failed to induce migration with any of these cell populations, whereas the respective positive control chemokines (CXCL12 and CXCL8) were effective (Fig. 4 C). Collectively, these experiments established that XCL1 is a chemokine with selective action on CD141+ DCs.

**CD141+ DCs efficiently cross-present antigen**

In the mouse system, XCR1 is exclusively expressed on a DC subset (bearing the surface marker CD8 in the spleen) known for its superior capacity to cross-present antigen in vivo (Dorner et al., 2009). We therefore decided to directly compare human CD141+ DCs with the other DC subtypes for antigen cross-presentation when purified from the blood of single donors. To this end, CD141+ DCs, CD1c+ DCs, CD16+ DCs, and pDCs from HLA-A*0201 donors were co-cultured with a CD8+ T cell clone recognizing the human CMV (HCMV) peptide NLVPMVATV (pp65495–503) when presented in the context of HLA-A*0201. Addition of recombinant pp65 protein in a soluble form to co-cultures with CD141+ DCs triggered strong IFN-γ secretion by the T cell clone, indicating an efficient intracellular degradation of pp65 and subsequent presentation of the NLVPMVATV peptide on the surface of this DC subset (Fig. 5 A). Addition of recombinant pp65 protein to co-cultures with CD1c+ or CD16+ DCs resulted in clearly lower IFN-γ signals; in the case of pDCs the signal was minimal (Fig. 5 A). Addition of OVA, a protein whose degradation products cannot be recognized by the T cell clone, gave only minimal background signals, as was the case in cultures containing only T cells or DCs (Fig. 5 A). Positive controls with the pp65 peptide...
The very low frequencies of pDCs and cDCs in human blood strongly impeded functional studies with primary populations in the past. As a result, data on antigen presentation, and in particular on antigen cross-presentation, remained scarce.

This limited information also made it difficult to directly compare human cDC subsets with the extensively characterized mouse cDC subtypes. In the mouse, it has been recognized that each DC subset is optimally equipped for the uptake, recognition, and presentation of different antigens or pathogens. One particular mouse cDC subset bearing the CD8 marker in the spleen (CD8+ DCs) very efficiently takes up antigen from the extracellular space and cross-presents it to CD8+ T cells when directly compared with all other human cDC subsets or pDCs; addition of 1 µg/ml of pp65495–503 peptide to the co-cultures served as a positive control. Shown is one representative experiment out of nine; each experiment was performed with cells from a different donor (all experiments included all cDCs subsets; four of them also included pDCs). (B) CD141+, CD1c+, or CD16+ DCs isolated from leukapheresis PBMCs of one HLA-A*0201+ donor were co-cultured with CD8+ T cell clone 61 at variable ratios (from 1:1 to 1:16) with cell-associated pp65 antigen added for the entire culture period, and IFN-γ was determined in the supernatant after 24 h. Negative controls included irrelevant MART-127–35 peptide, and positive controls included HCMV pp65495–503 peptide (both at 1 µg/ml). Shown are results representative of three experiments with different donors. Error bars represent mean ± SEM.

DISCUSSION

The very low frequencies of pDCs and cDCs in human blood strongly impeded functional studies with primary populations in the past. As a result, data on antigen presentation, and in particular on antigen cross-presentation, remained scarce. This limited information also made it difficult to directly compare human cDC subsets with the extensively characterized mouse cDC subtypes. In the mouse, it has been recognized that each DC subset is optimally equipped for the uptake, recognition, and presentation of different antigens or pathogens. One particular mouse cDC subset bearing the CD8 marker in the spleen (CD8+ DCs) very efficiently takes up antigen from the extracellular space and cross-presents it to CD8+ T cells (den Haan et al., 2000; Iyoda et al., 2002; Schulz and Reis e Sousa, 2002; Heath et al., 2004). This professional antigen cross-presentation is regarded as important for the immune defense of intracellular viral and bacterial pathogens, as well as for the eradication of tumor tissue (Lin et al., 2008; Shortman and Heath 2010). We have recently shown that these mouse splenic CD8+ DCs (and their counterparts in other organs) exclusively express the chemokine receptor XCR1 and selectively migrate to its chemokine ligand XCL1 (Dorner et al., 2009).

We now have developed an effective scheme for the isolation of all currently defined human DC subsets, including pDCs (CD304+) and cDCs (CD1c+, CD16+, or CD141+) to a very high purity from single-blood donations. This approach allowed us to search for the human counterpart of the cross-presenting mouse CD8+ DCs. In the past, concordant expression of certain cell-surface molecules on both human CD141+ DCs and mouse CD8+ DCs led to initial suggestions that these two DC subsets may be related (Galibert et al., 2005; Caminschi et al., 2008). By meticulously comparing the gene expression patterns of all known human and mouse DC subsets, a recent study substantiated these suggestions (Robbins et al., 2008). In our current work, we now demonstrate that CD141+ DCs, which represent only ~3–4% of all DCs in human blood, exclusively express the chemokine receptor XCR1 and selectively respond to the chemokine ligand XCL1 by [Ca2+] mobilization and chemotaxis. More importantly in terms of biological function, we now show that CD141+ DCs excel in cross-presentation of antigen to CD8+ T cells when directly compared with all other human CD8+ T cells.
pDC and cDC subsets in vitro. Collectively, these results define CD141+ DCs as professional antigen–cross-presenting DCs in the human and allow the conclusion that this DC subset is the homologue of mouse CD8+ DCs.

The identification of professional human cross-presenting DCs is an important step forward, because it indicates that the biological concepts on antigen cross-presentation derived from extensive experimentation in the mouse can apparently be transferred to the human. However, many questions remain to be answered. For example, the identification of cross-presenting DCs in the blood raises the issue of whether these cells are also resident in lymphoid tissues and other organs. Our preliminary data clearly point in this direction. In the thymus, we could observe that CD141+ cDCs express XCR1 mRNA, and CD141+ cells obtained from tonsillectomies also gave substantial PCR signals for XCR1. Attempts to locate human CD141+ DCs in lymphoid tissues using histology were confounded by a relatively diffuse expression pattern obtained in areas populated by lymphoid cells and by the dominant expression of CD141 on the endothelium (Esmon et al., 1982). A definitive proof of the presence of human DCs capable of antigen cross-presentation in lymphoid tissues will require further phenotypic dissection of the local DC subtypes combined with antigen presentation studies in vitro.

We are not aware of any data in the literature on the capacity of CD141+ DCs to present or cross-present antigen to T cells. With other primary human DC subsets, functional data on cross-presentation are very scarce. Schnurr et al. (2005) functionally compared primary CD1c+ DCs (cultured overnight with GM-CSF) with primary pDCs (cultured with IL-3) and found only CD1c+ DCs capable of antigen cross-presentation to CD8+ T cells, whereas pDCs were totally ineffective. In contrast, Hoeffel et al. (2007) reported a similar cross-presentation by cDCs and pDCs, and Di Pucchio et al. (2008) also found a comparable cross-presentation capacity of CD1c+ DCs and pDCs. In neither of the cited reports have CD141+ DCs been removed before experimentation, but this technical aspect is unlikely to be the cause for the differing results, because the frequency of CD141+ DCs within the tested DC populations is so low. Instead, other technical details may have influenced the results. Hoeffel et al. (2007), e.g., have used a lipopeptide as a source of antigen (for a short-term assay), whereas Di Pucchio et al. (2008) assessed antigen cross-presentation by quantifying CD8+ T cell proliferation over 6 d. In our experiments, CD141+ DCs were clearly superior to CD1c+ and CD16+ DCs in their capacity to cross-present soluble or cell-associated antigen to CD8+ T cells in a short-term, highly quantitative assay system in which survival of all tested DC subpopulations was similar. In the same setup, pDCs were consistently ineffective.

The tight correlation between the expression (and function) of the chemokine receptor XCR1 and the capacity of DCs to cross-present antigen in the mouse and in the human is suggestive of a biological linkage. We have previously demonstrated that XCL1, the only known chemokine ligand for XCR1, is coexpressed with IFN-γ by NK cells and CD8+ T cells upon activation in vitro (Dorner et al., 2002). Further, in the mouse Listeria infection model, XCL1 was secreted by NK cells in the early phase of the infection and by antigen-experienced CD8+ T cells in the recall response (in each instance together with IFN-γ). These observations led to the concept of XCL1 and IFN-γ acting (together with other cytokines) as a functional cytokine unit in the defense of certain infections (Dorner et al., 2002). With the recognition of cross-presenting DCs as the only cells bearing XCR1, this concept can be further refined. Thus, in the early innate response, XCL1 may ensure contact and thus exchange of information between activated NK cells and XCR1-bearing DCs. Later, in the adaptive phase and on reexposure, this cytokine functional unit is handed over to CD8+ T cells and thus ensures proper communication between cross-presenting DCs and CD8+ T cells (Fig. 6), as also demonstrated experimentally (Dorner et al., 2009). The XCL1–XCR1 communication axis thus apparently optimizes the differentiation and function of innate and adaptive cytotoxic cells required for an effective response against certain (intracellular?) pathogens.

Finally, the identification of human professional cross-presenting DCs provides new avenues for the development of antiviral and antitumor vaccines based on the induction of cytotoxic T cells (Steinman and Banchereau, 2007; Andrews et al., 2008; Caminschi et al., 2009). The involvement of the

![Diagram of XCL1–XCR1 Communication Axis](image)
XCL1–XCR1 communication axis in the innate and adaptive cytotoxic responses against certain infections (and possibly also tumors) makes XCR1 an interesting target for the delivery of prophylactic or therapeutic vaccines to cross-presenting DCs. The selectivity of XCR1 expression on these DCs, unmatched by any other known cell-surface molecule, and the typical internalization of chemokine receptors upon ligand binding further make this targeting route attractive.

**Materials and Methods**

**Antibodies and flow cytometry.** Antibodies recognizing CD19 (clone BU12; Flavell et al., 1995), CD3 (OKT3), CD14 (63D3), HLA-DR (L243; all from American Type Culture Collection), CD11c (BU15), CD15 (W6D3), CD16 (5G8), CD45 (HI30), CD56 (HCD56), HLA-A2 (BB7.2; BioLegend), CD1c (AD5-8E7), CD141 (AD5-14H12), and CD304 (AD5-17F6; Miltenyi Biotec) were used. Data were acquired on a flow cytometer (LSR II; BD) and analyzed using FlowJo software (Tree Star, Inc.).

**Cell isolation for RNA preparation, fluorometric [Ca2+]i determination, and cross-presentation assays.** PBMCs were prepared by standard Briccol (Biocrom) density gradient centrifugation of buffy coats from preoperative autologous deposits or of peripheral blood cells obtained from volunteers by leukapheresis. Leukapheresis was based on written informed consent and was approved by the local ethics committee. For preparation of granulocytes, whole blood was subjected to erythrocyte lysis with ACK buffer (155 mM NaCl, 10 mM KHCO₃, 0.1 mM EDTA) followed by flow sorting (CD45+, CD15−, CD3−, CD14−, CD19−, CD141−) to a purity >99.7%. T cells (CD3+, CD19−, CD141−), B cells (CD19+, HLA-DR+, CD3−, CD141−), NK cells (CD16−, CD56−, CD3−, CD141−, HLA-DR−), and monocytes (CD14+, CD3−, CD19−, CD141−) were flow sorted from PBMCs to a purity >99.4%. DC1c+ DCs (CD1c+, CD11c+, HLA-DR+, CD141−, CD16−, CD14−, lin−; ≥99.5% pure), CD16+ DCs (CD16+, CD11c−, HLA-DR−, CD141−, lin−; ≥99.2% pure), CD141+ DCs (CD141+, CD11c+, HLA-DR−, CD16−, CD14−, lin−; ≥97.5% pure), and pDCs (CD304+, HLA-DR−, CD11c−, CD14−, lin−; ≥99.9% pure) were flow sorted from PBMCs after magnetic enrichment with the respective cell isolation kits from Miltenyi Biotec. In all flow sorting experiments, cells were preincubated with 2 µg/ml Endobulin (Baxter Hyland-Immuno Division) for 5 min at 4°C to block unspecific binding of mAbs. Flow sorting of cells was performed on a cell sorter (FACSaria II; BD). For generation of MoDCs, monocytes were enriched from PBMCs with CD14 microbeads and cultured for 5 d in RPMI 1640 medium supplemented with 10% FCS, penicillin, streptomycin, 500 U/ml GM-CSF, and 100 U/ml IL-4.

**PCR.** Total RNA was prepared using the High Pure RNA Isolation Kit (Roche). RNA concentration, purity, and integrity were determined on a 2100 Bioanalyzer (Agilent Technologies) and by photometric reading on a NanoDrop 1000 (Thermo Fisher Scientific). For determination of XCR1 expression, 100 ng of total RNA were reverse transcribed into cDNA with hexamer primers and the AMV Reverse Transcriptase System (Promega), and analyzed by quantitative PCR using the following primer–probe sets: 5′-TACAAGGACATGTTAAAGGAGTGTG-3′ (forward primer F1), 5′-GGTGCGCTGAGCTCTCACTGCT-3′ (reverse primer R1), and 5′-FAM-TGCTCTAAGCTCCTGGACATCTGCT-3′ (reverse primer R2), and 5′-FAM-CATCCAGCTCTACAGAGCTCATT-3′ (forward primer F2), 5′-GGCTGTGATGTGCTATGGTGG-3′ (reverse primer R2), and 5′-FAM-TGCTGCAATCTCAGAGCTCATT-3′ (probe P2). Amplification of β2-microglobulin was used as a positive control: 5′-GCCCGTGAGGACATGTGCTATGCT-3′ (forward), 5′-CGGCAATCCCAACCTCCTCCCA-3′ (reverse), and 5′-FAM-TGATGGGATGCGGACATGTAAGCGACATC-TAMRA-3′ (probe). To generate standards for mRNA/cDNA copy quantitation, the specific XCR1 gene fragments were amplified and cloned into pJET1.2 vectors using the CloneJET PCR cloning kit (Fermentas). For quantitative PCR, primers were mixed with 10 µl Absolute QPCR Mix including R.OX (Aligene) and 1/10 of the cDNA in a 20-µl PCR reaction. PCR was performed and quantified on a 7500 Fast Real-Time PCR System (Applied Biosystems) with initial enzyme activation at 95°C for 15 min, followed by 40 cycles (95°C for 15 s and 60°C for 1 min).

**Fluorometric [Ca2+]i determination.** CD141+, CD1c+, and CD16+ DCs were freshly flow sorted to a purity >98.7%, as described in Cell isolation for RNA preparation... The sorted cell suspensions were washed (200 for 5 min) and resuspended in Hepes-buffered solution (HBS) containing 128 mM NaCl, 6 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂, 5.5 mM glucose, 10 mM Hepes, and 0.2% BSA, supplemented with 2 µM fura-2/AM (Invitrogen). Cell suspensions were allowed to settle and adhere on poly-L-lysine–coated glass coverslips at 37°C and 5% CO₂ for 30 min in a humidified atmosphere. Coverslips were superfused with HBS, mounted in a bath chamber, and imaged with an inverted microscope (Axiovert 100; Carl Zeiss, Inc.) using a UV-transmissive 10×/0.5 Fluar objective. During and after application of 1,000 ng/ml XCL1 or a chemokine mix (100 ng/ml CCL2, 200 ng/ml CCL21, 200 ng/ml CXCL9, 1 ng/ml CX3CL1) as a positive control, the fura-2/AM fluorescence was sequentially excited with monochromatic light of 340, 358, and 380 nm, and fluorescence emission was detected through a 512-nm-long pass filter with a cooled charge-coupled device camera (TILL-Photomics). Signals arising from the bound and unbound Ca²⁺ indicator were averaged over regions of interest that covered the area of single immobilized cells. Spectrally overlapping signals were separated and [Ca²⁺], was calculated by a spectral fingerprinting method (Lenz et al., 2002). To assess a possible impact of contaminating fluorescence arising from fluoro-chrome-labeled antibodies, cell suspensions were treated and imaged in a similar way but without fura-2/AM loading. Under these conditions, there were no fluorescence signals discernible when excited at 340, 358, or 380 nm; we thus conclude that the fluorescence signals required no additional preprocessing.

**Chemotaxis assay.** For chemotaxis assays, 10⁶ cells suspended in 100 µl of medium (RPMI 1640; 1% BSA, 50 µM β-ME, 100 µg/ml penicillin/streptomycin) were placed into the upper chamber of a Transwell-24 system (6.5-mm diameter, 5-µm pore polycarbonate membrane; Costar, Corning). The lower chamber was filled with chemotaxis medium containing recombinant human XCL1 (R&D Systems) or any of the chemokines CCL2 (100 ng/ml), CCL21 (200 ng/ml), CXCL1 (1 ng/ml), CXCL12 (200 ng/ml) for T cells, B cells, NK cells, and monocytes; 100 ng/ml for pDCs, and CXCL8 (100 ng/ml; all from R&D Systems), and the cells were incubated for 150 min at 37°C in 5% CO₂. In the lower chamber, cDCs (CD141+, CD1c+, CD16+), pDCs (CD304+, HLA-DR+, CD11c+, CD3−, CD14−, CD19−, CD56−), T cells (CD3+, CD19+, CD14−, CD14), B cells (CD19+, CD3−, CD14−), NK cells (CD56−, CD16−, CD3−, CD14−, CD19−), monocytes (CD14+, CD3−, CD14−), and granulocytes (CD15+, CD14−, CD16−) were identified by the indicated markers using flow cytometry. The absolute number of input or migrated cells was determined by counting all cells in a defined volume with a flow cytometer, and the percentage of migrated cells was calculated by dividing the number of cells in the lower chamber by the number of input cells (number of migrated cells/number of input cells × 100). All experiments were performed with duplicate wells.

**HCV pp65-specific CD8+ T cell clone.** An HLA-A*0201– restricted, HCV pp65–specific CD8+ T cell clone was prepared according to the procedure of Fonteneau et al. (2001). In brief, T cells from an HLA-A*0201+ donor were stimulated with autologous mature MoDCs, which were pulsed with pp65 (50–600). The activated T cells were expanded and cloned by limiting dilution; two of the pp65–specific CD8+ T cell clones (clones 10 and 61) were further expanded on irradiated feeder cells (an EBV line [2 × 10⁶ cells/well] and PBMCs [2 × 10⁶ cells/well], both irradiated...
with 43 Gy) using 1 μg/ml leucoagglutinin PHA-L (Sigma-Aldrich) and 150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

Cross-presentation assay. Soluble recombinant HCMV pp65 (low endotoxic) was obtained from Miltenyi Biotec. Recombinant OVA (Sigma-Aldrich), from which LPS was removed using EndoTrap red (Hyglos), resulting in <0.5 U of endotoxin per milligram of protein as determined by the LAL assay (Charles River), was taken up in the same buffer as recombinant pp65. For cell-associated pp65 antigen, full-length HCMV pp65 cDNA cloned into the pcDNA3.1/myc-His vector (24 μg) was mixed with 24 μl Lipofectamine 2000 in 3 ml of Opti-MEM medium (all from Invitrogen) and used to transfect 2 × 105 HeLa cells (American Type Culture Collection) overnight according to the manufacturer's instructions. Transfected HeLa cells were trypsinized, adjusted to 2 × 105 cells/ml in RPMI 1640 containing 10% FCS, and subjected to four freeze-thaw cycles. Transfection efficiency was monitored by Western blotting of 5 μg of protein lyase (determined with a BCA Protein Assay; Thermo Fisher Scientific) using HCMV pp65 mAb (CH12; Santa Cruz Biotechnology, Inc.). Cross-presentation of pp65 antigens by DCs was examined as described previously (Fonteneau et al., 2003). In brief, highly purified DC subtypes were incubated with a T cell clone in round-bottom 96-well plates in RPMI 1640, previously adjusted to 2 × 105 cells/ml in RPMI 1640 containing 10% FCS, and subjected to four freeze-thaw cycles. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.

150 U/ml of recombinant IL-2. Before being used in an assay, the T cell clones were rested for at least 10 d.


